Elixir Medical Completes Enrollment in Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Trial is evaluating DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance.

Related Keywords

Japan ,Kanagawa ,Fukushima ,United States ,New Zealand ,Coll Cardiol ,Shigeru Saito ,Austrian Wiktor Stent Study Group ,Catheterization Laboratory At Shonan Kamakuru ,Elixir Medical ,Dynamx Coronary Bioadaptor System ,Dynamx Bioadaptor ,Resolute Onyx ,Catheterization Laboratory ,Shonan Kamakuru General Hospital ,Circ Cardiovasc ,Year Follow Up ,Randomized Controlled Trial ,Paclitaxel Eluting Stents ,Coronary Revascularization ,Varying Outcomes With ,Absorb Bioresorbable Vascular Scaffold During ,Systematic Meta Analysis ,Individual Patient Data Pooled ,Wiktor Stent Study Group ,European Paragon Stent ,Cardiovascular Revascularization Medicine ,